SDGR-3 is under clinical development by Schrodinger and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Chronic Lymphocytic Leukemia (CLL) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SDGR-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SDGR-3 overview

SDGR-3 is under development for the treatment of BTK-resistant or relapsed B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. It is administered through oral route. It acts by oncogenic activation of nuclear factor-kappa B which acts by targeting MALT1 activity. MALT1 is the mucosa-associated lymphoid tissue lymphoma translocation gene 1 which plays an important role in NF-kappaB activation. MALT1 enzymatic activity is implicated in the development of inflammatory, autoimmune disorders and lymphomas. It is developed based on the Schrodinger artificial intelligence (AI) technology.

Schrodinger overview

Schrodinger is a software technology company that provides computation software solutions for drug discovery. It operates through its software and drug discovery divisions. The company’s software division offers a computational platform designed with predictive modeling, data analytics, and collaboration applicable in molecular discovery. Schrodinger is investigating SGR-1505 (MALT1) against non-Hodgkin’s lymphoma; SGR-2921 (CDC7) to treat hematological cancers and solid tumors; and Wee1 for gynecological cancers and other solid tumors through its drug discovery segment. It is also evaluating programs against oncology, immunology and neurology indications. The company serves biopharmaceutical companies, academic institutions, and government laboratories. Schrodinger is headquartered in New York, the US.

For a complete picture of SDGR-3’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.